Precision therapy in RAS mutant colorectal cancer

The consensus molecular subtypes of colorectal cancer

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · see citing works

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,178 · see citing works

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works

Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors

Li, H., Courtois, E. T., Sengupta, D., Tan, Y., Chen, K. H., Goh, J. J. L., Kong, S. L., Chua, C., Hon, L. K., Tan, W. S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3818 · Cited by 1,080 · see citing works

Ras in Cancer and Developmental Diseases

Fernández‐Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 959 · see citing works

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Byrne, A. T., Alférez, D., Amant, F. C., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budínská, E., Caldas, C., Chang, D. K.-F., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.140 · Cited by 663 · see citing works

KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · see citing works

Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy

Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590 · see citing works

Therapeutic strategies to target RAS-mutant cancers

Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · see citing works

Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

Isella, C., Brundu, F. G., Bellomo, S. E., Galimi, F., Zanella, E. R., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 298 · see citing works

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270 · see citing works

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

Dienstmann, R., Mason, M. J., Sinicrope, F. A., Phipps, A. I., Tejpar, S., Nesbakken, A., Danielsen, S. A., Sveen, A., Buchanan, D. D., Clendenning, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx052 · Cited by 240 · see citing works

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients

Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215 · see citing works

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2683 · Cited by 191 · see citing works

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183 · see citing works

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

Zdanov, S., Mandapathil, M., Eid, R. A., Adamson-Fadeyi, S., Wilson, W., Qian, J., Carnie, A., Tarasova, N. I., Mkrtichyan, M., Berzofsky, J. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0241 · Cited by 157 · see citing works

KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer

Lal, N., White, B. S., Goussous, G., Pickles, O. J., Mason, M. J., Beggs, A. D., Tanière, P., Willcox, B. E., Guinney, J., & Middleton, G. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1090 · Cited by 154 · see citing works

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 139 · see citing works

Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Siravegna, G., Bianchi, A. S., Nagy, R. J., Raghav, K. P. S., Odegaard, J. I., Lanman, R. B., Trusolino, L., Marsoni, S., Siena, S., & Bardelli, A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3389 · Cited by 134 · see citing works

Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers

Yau, E. H., Kummetha, I. R., Lichinchi, G., Tang, R., Zhang, Y., & Rana, T. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2043 · Cited by 117 · see citing works

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy

Smeets, D., Miller, I. S., O’Connor, D. P., Das, S., Moran, B., Boeckx, B., Gaiser, T., Betge, J., Barat, A., Klinger, R. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06567-6 · Cited by 81 · see citing works

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80 · see citing works

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

Bendell, J. C., Ciardiello, F., Tabernero, J. M., Tebbutt, N. C., Eng, C., Bartolomeo, M. D., Falcone, A., Fakih, M., Kozloff, M. F., Segal, N. H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy208.003 · Cited by 50 · see citing works

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

Lieu, C. H., Hidalgo, M. M., Berlin, J. D., Ko, A. H., Cervantes, A. M. R., LoRusso, P. M., Gerber, D. E., Eder, J. P., Eckhardt, S. G., Kapp, A. V., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0175 · Cited by 28 · see citing works

Spectrum of Gene Mutations in Colorectal Cancer

Dienstmann, R., & Tabernero, J. M. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000191 · Cited by 26 · see citing works

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations

Pal, R., Wei, N., Song, N., Wu, S., Kim, R. S., Wang, Y., Gavin, P. G., Lucas, P. C., Srinivasan, A., Allegra, C. J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200836 · Cited by 12 · see citing works

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482 · see citing works

Strategies to tackle RAS-mutated metastatic colorectal cancer

Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86 · see citing works

Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage

Ternet, C., & Kiel, C. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00712-3 · Cited by 69 · see citing works

Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology

László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021) · Cells · doi:10.3390/cells10030667 · Cited by 58 · see citing works

Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments

Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58 · see citing works

Precision medicine for metastatic colorectal cancer in clinical practice

Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 57 · see citing works

Myeloid‑derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)

Zeng, W., Liu, H., Mao, Y., Jiang, S., Hao, Y., Zhang, Z., Wang, M., & Zong, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5673 · Cited by 41 · see citing works

Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer

Lai, E., Liscia, N., Donisi, C., Mariani, S., Tolu, S., Pretta, A., Persano, M., Pinna, G., Balconi, F., Pireddu, A., et al. (2020) · Cancers · doi:10.3390/cancers12051214 · Cited by 37 · see citing works

Iron metabolism in colorectal cancer

Huang, L., Li, W., Lu, Y., Ju, Q., & Ouyang, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098501 · Cited by 34 · see citing works

Current therapy of advanced colorectal cancer according to RAS/RAF mutational status

Lakatos, G., Köhne, C., & Bodoky, G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09913-7 · Cited by 30 · see citing works

First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial

Wang, Z., Peng, J., Liang, X., Cheng, Y., Deng, Y., Chen, K., Zhang, M., Zhang, J., Wang, W., Cao, B., et al. (2024) · Med · doi:10.1016/j.medj.2024.05.009 · Cited by 22 · see citing works

Serum copper status of patients with colorectal cancer: A systematic review and meta-analysis

Squitti, R., Pal, A., Dhar, A., Shamim, M. A., Ventriglia, M., Simonelli, I., Rani, I., Sharma, A., Rizzo, G., Tondolo, V., et al. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127370 · Cited by 22 · see citing works

Overcoming Obstacles to Targeting Muscarinic Receptor Signaling in Colorectal Cancer

Ali, O., Tolaymat, M., Hu, S., Xie, G., & Raufman, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020716 · Cited by 21 · see citing works

Colorectal cancer murine models: Initiation to metastasis

Pothuraju, R., Khan, I., Jain, M., Bouvet, M., Malafa, M. P., Roy, H. K., Sushil Kumar, K., & Batra, S. K. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216704 · Cited by 21 · see citing works

Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma

Zheng, Y., Peng, H., Xu, H., Ou, Y., Wang, D., Wang, H., & Ren, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199395 · Cited by 16 · see citing works

Comparison of Intratumoral and Peritumoral Deep Learning, Radiomics, and Fusion Models for Predicting KRAS Gene Mutations in Rectal Cancer Based on Endorectal Ultrasound Imaging

Gan, Y., Hu, Q., Shen, Q., Peng, L., Qian, Q., Zhuo, M., Xue, E., & Chen, Z. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16697-5 · Cited by 14 · see citing works

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Élez, E., Cubillo, A., Alfonso, P., Middleton, M. R., Chau, I., Alkuzweny, B., Alcasid, A., Zhang, X., & Cutsem, E. V. (2024) · BMC Cancer · doi:10.1186/s12885-024-12153-5 · Cited by 12 · see citing works

An exosome-based nanoplatform for siRNA delivery combined with starvation therapy promotes tumor cell death through autophagy, overcoming refractory KRAS-mutated tumors and restoring cetuximab chemosensitivity

Xiang, Y., Liu, Q., Liu, K., Chen, L., Chen, F., Li, T., Li, S., Yu, Q., Lv, Q., & Xiang, Z. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101732 · Cited by 11 · see citing works

Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer

Gonzalez, N. S., López-Valbuena, D., Gómez, D., Ros, J., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2160316 · Cited by 11 · see citing works

NF-κB-activated oncogene inhibition strategy for cancer gene therapy

Dai, W., Wu, J. Y., Shui, Y., Wu, Q., Wang, J., & Xia, X. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00828-x · Cited by 11 · see citing works

RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches

Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10 · see citing works

Beyond Detection: Conventional and Emerging Biomarkers in Gastrointestinal Cancers

Han, D. M., Wakefield, M. R., & Fang, Y. (2025) · Cancers · doi:10.3390/cancers17172725 · Cited by 10 · see citing works

The Importance of KRAS Quantification for a Clinicopathological Characterization in Colorectal Cancer Patients

Bratei, A. A., & Staden, R. S. (2023) · Medinformatics · doi:10.47852/bonviewmedin32021546 · Cited by 9 · see citing works

KRAS/NRAS/BRAF mutational profile and association with clinicopathological characteristics in patients with metastatic colorectal cancer

Abudalo, R. A., Alqudah, A. M., Alnajjar, R., Abudalo, R., Abuqamar, A., Oqal, M. K., & Qnais, E. Y. (2025) · Oncology Letters · doi:10.3892/ol.2025.15058 · Cited by 8 · see citing works

Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I–III colorectal cancer

Wang, W., Wang, R., Han, X., Zhang, W., Zhu, L., & Gu, Y. (2024) · Medicine · doi:10.1097/md.0000000000037693 · Cited by 8 · see citing works

Targeting KRAS in colorectal cancer (Review)

Zhang, M., Wu, D., Tang, C. Y. L., Zhang, L., Zhang, S., Li, W., Li, N., & Yan, X. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2873 · Cited by 7 · see citing works

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

Cardone, C., Stefano, A. D., Rosati, G., Cassata, A., Silvestro, L., Borrelli, M., Gennaro, E. D., Romano, C., Nappi, A. G., Zanaletti, N., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100748 · Cited by 7 · see citing works

Prediction of KRAS gene mutations in colorectal cancer using a CT-based radiomic model

Wang, W., Zhang, Q., Fan, S., Wang, Y., Le, X., Ai, M., Du, C., Feng, J., & Li, C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1592497 · Cited by 6 · see citing works

THERAPEUTIC TARGETING OF MOLECULAR PATHWAYS IN COLORECTAL CANCER

Nur, A. E. (2022) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-44-no-1.17455 · Cited by 5 · see citing works

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 5 · see citing works

Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS

Dorandish, S., Bhayekar, K., Singh, A., Kushwaha, N. D., Malin, E., Serafimovski, S., Kelm, J. M., Gavande, N. S., & Lakkaniga, N. R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00169b · Cited by 5 · see citing works

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions

Zhu, G., Pei, L., Ye, D., Tang, Q., Xu, H., & Bi, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189382 · Cited by 5 · see citing works

Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer

Jayachandran, P., Elliott, A., Soni, S., Battaglin, F., Mittal, P., Algaze, S., Lo, J. H., Yang, Y., Ashouri, K., Torres, E. T. R., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03484-z · Cited by 5 · see citing works

Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity

Hong, S., Jeon, M., Kwon, J., Park, H., Lee, G., Kim, K., & Ahn, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45070371 · Cited by 5 · see citing works

Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

Toledo, D. C., Jiménez‐Fonseca, P., López, C., Montés, A. F., Muñoz, A. M. L., Rivera, F. V., Alonso, V., Alcaide, J., Salvà, F., Rúa, M. C., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02563-w · Cited by 5 · see citing works

Predictive “omic” biomarkers of drug response: Colorectal cancer as a model

Mini, E., Landini, I., Paolo, A. D., Ravegnini, G., Saponara, S., Frosini, M., Lapucci, A., & Nobili, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00002-0 · Cited by 5 · see citing works

Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer

Kavgacı, G., Dızdar, Ö., & Yalçın, Ş. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001587 · Cited by 5 · see citing works

Translational Suppression of KRAS and NRAS via RNA G-Quadruplex-Targeting Small Molecules for Colorectal Cancer Therapy

Zheng, B., Chen, Z.-X., Wang, Y.-K., Dong, J.-P., She, M., Zheng, Y., Zeng, Y.-X., Zheng, W.-D., Long, W. S., & Wong, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03088 · Cited by 4 · see citing works

Role of blood metabolites in mediating the effect of gut microbiome on the mutated-RAS/BRAF metastatic colorectal cancer-specific survival

Xiang, Y., Zhang, C., Wang, J., Cheng, Y., Wang, K., Wang, L., Tong, Y., & Yan, D. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04686-9 · Cited by 4 · see citing works

Investigating the Pathogenicity of Uncommon KRAS Mutations and Their Association with Clinicopathologic Characteristics in Patients with Colorectal Cancer

Adorisio, R., Ciardiello, D., Rappa, A., Gervaso, L., Pelizzari, G., Marinucci, L., Fusco, N., Zampino, M. G., Fazio, N., Venetis, K., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.11.007 · Cited by 4 · see citing works

Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania

Pîrvu, E. E., Severin, E. M., Pătru, R. I., Niță, I., Toma, Ş. A., Macarie, R. R., Cocioabă, C. E., Florescu, I., & Coniac, S. (2023) · Diagnostics · doi:10.3390/diagnostics13182930 · Cited by 4 · see citing works

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type <i>RAS</i> Metastatic Colorectal Cancer

Van Cutsem, E., Yaeger, R., Delord, J.-P., Tabernero, J., Siu, L. L., Ducreux, M., Siena, S., Elez, E., Kasper, S., Zander, T., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad210 · Cited by 3 · see citing works

Exploring the role of monocarboxylate transporter 4 in diverse KRAS mutation subtypes of colorectal Cancer

Gong, Q., Huang, J., Li, Q., Zhang, S., Xiao, M., Li, M., Yang, Y., Tang, Y. P., & Wang, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-06254-9 · Cited by 3 · see citing works

Clinicopathological and molecular characteristics of colorectal adenosquamous carcinoma in an Asian population

Ye, F., Chen, M., Zheng, X., Huang, P., Wang, C., Liu, H., Xie, H., Xiao, W., Guo, Q., & Huang, L. (2024) · BMC Gastroenterology · doi:10.1186/s12876-023-02989-9 · Cited by 3 · see citing works

Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer

Park, Y. S., kim, J., Ryu, Y. S., Moon, J.-H., Shin, Y. J., Kim, J. H., Hong, S., Jung, S.-A., Lee, S., kim, S.-M., et al. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2246208 · Cited by 3 · see citing works

EIF3B Promotes KRAS Gene Mutation‐Driven Colon Adenocarcinoma Progression Through the TBK1 and PI3K/AKT Signaling Pathways

Ren, C., Qin, Y., Cao, D., Ren, X., Zhao, H., Han, J., & Du, G. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70353 · Cited by 2 · see citing works

Combining KRAS gene status with preoperative D‑dimer levels as a predictive marker of venous thromboembolism risk in patients with resectable colorectal cancer: A prospective cohort study

Xu, D., He, Y., Liao, C., & Tan, J. Y. (2024) · Biomedical Reports · doi:10.3892/br.2024.1784 · Cited by 2 · see citing works

Systemic Therapy for Metastatic Colon Cancer: New Frontiers

Pumpalova, Y. S. (2024) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0044-1787826 · Cited by 2 · see citing works

The 5-/12-lipoxygenase-BLT2 cascade induces elevated expression of c-Myc, thus mediating the proliferation and migration of KRAS mutant colorectal cancer cells

Park, J., Jang, J.-H., Wei, J., & Kim, J. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2290031 · Cited by 2 · see citing works

Adagrasib plus cetuximab – a novel therapy in the KRAS G12C mutated colorectal cancer treatment

Khan, A., Chawla, S., Hussain, T., & Haque, M. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002777 · Cited by 2 · see citing works

Применение панелей комплексного молекулярного профилирования при опухолях желудочно-кишечного тракта. Обзор литературы и собственные результаты

Kuznetsova, O. A., Федянин, М. Ю., Ivanov, M. V., Трякин, А. А., Borshchev, G. G., Lebedeva, A., Михайлович, В. Е., Витальевич, Л. Е., Shamrikova, V., Stepanova, M., et al. (2023) · Malignant tumours · doi:10.18027/2224-5057-2023-13-3s1-7-17 · Cited by 1 · see citing works

Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer

Kim, D., Sharif, S., Garay, J. A. R., Bhakta, A. S., Boland, P. M., Cavnar, M. J., Churchman, M. L., Hatoum, H. A., Huang, L. C., Kim, J., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71114 · Cited by 1 · see citing works

KRAS Mutations in Colorectal Adenocarcinoma: Incidence and Association with Histological Features with Particular Reference to Gly12Asp in a Multicenter GIPAD Real-World Study

Parente, P., Angerilli, V., Grillo, F., Ambrosio, M. R., Petrelli, F., Gasparello, J., Antoci, F., Pilozzi, E., Scarpino, S., Adotti, F., et al. (2025) · Cancers · doi:10.3390/cancers17172721 · Cited by 1 · see citing works

The KRAS-G12D mutation drives venous thromboembolism (VTE) and colorectal cancer progression via MAPK/ERK signaling

Mao, J., Xu, M. J., Wang, M., Du, Y., Shen, Y., Li, D., Zhu, Z., Li, X., & Li, J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102529 · Cited by 1 · see citing works

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science

Boby, J. M., Ilerhunmwuwa, N. P., Benny, J. M., Peniche, P. Z., Baytar, D. K., & Sahin, I. H. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2636581 · Cited by 1 · see citing works

Saturation Genome Editing Targeting KRAS Mutations in HCT 116 Colon Carcinoma Cells for Pooled SNV Functional Profiling in Diploid Cancer Model

Hamada, T., Yokoyama, S., Nakabayashi, R., Suzuki, Y., Morishita, S., Akahane, T., Matsuo, K., Kitazono, I., Furukawa, T., & Tanimoto, A. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040341 · Cited by 1 · see citing works

Co-clinical CT radiomics pipeline to establish candidate imaging biomarkers for colorectal cancer

Connor, K., Prior, O., Shiels, L. P., Connolly, C., Miller, I. S., Crean, R., Murphy, S., McGuinness, G., Monreal‐Agüero, C., Serna, G., et al. (2026) · European Journal of Radiology · doi:10.1016/j.ejrad.2026.113038 · Cited by 1 · see citing works

Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations.

Liu, P., Jiao, F., Zhang, Z., Zhao, F., Cai, J., Chen, S., Fu, T., & Li, M. (2022) · PubMed Central · Cited by 1 · see citing works

Application Advances in Deep Learning-Based Imaging Radiomics for Predicting Colorectal Cancer Gene Status

李, 鹏. (2024) · World Journal of Cancer Research · doi:10.12677/wjcr.2024.141005 · Cited by 1 · see citing works

Delivering a RAS protease halts tumor growth

Vidimar, V., Melnyk, R. A., & Satchell, K. J. F. (2020) · Oncotarget · doi:10.18632/oncotarget.27714 · Cited by 1 · see citing works

Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases

Das, S., & Berlin, J. D. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.08.008

To Explore Genes Related to the Prognosis of Colorectal Cancer

Chen, M., Tan, Q., Yin, T., & Wang, C. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.631

The adiposity of CRLM before targeted therapy initiation may serve as a marker to distinguish KRAS mutation status：A retrospective studyPreprint

Xiao, R., Wang, N., Xiao, W., & Liu, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4136576/v1

Combining Senescence-related lncRNA and Bulk-RNA Transcriptome Sequencing to Construct a Prognostic Model and Identify TSPEAR−AS2 as a Potential Therapeutic Target for Colon Adenocarcinoma PatientsPreprint

Liang, X., Cai, X., Zhang, D., Meng, X., Wang, K., Liu, Y., Hao, M., Li, H., & Ding, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4196799/v1

Treatment Strategies’ Impact on Progression-Free Survival According to RMST Function in Metastatic Colorectal Cancer Patients: A Retrospective Study from Romania

Pirvu, E. E., Severin, E. M., Pătru, R. I., Niță, I., Toma, Ş. A., Croitoru, B. E., Groza, A. E. M., & Marinescu, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206174

Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases

Das, S., & Berlin, J. D. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.08.008

Single-Cell RNA Sequencing Reveals Characteristics of Myeloid Cells and Fibroblasts in RAS-Mutated Colorectal CancerPreprint

He, Q., Sheng, N., Wang, J., Gong, J., Gu, Y., Liu, Z., Jiao, Q., Chen, H., Zhang, Z., & Wang, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6741598/v1

Additional file 1 of Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Élez, E., Cubillo, A., Alfonso, P., Middleton, M. R., Chau, I., Alkuzweny, B., Alcasid, A., Zhang, X., & Cutsem, E. V. (2024) · Figshare · doi:10.6084/m9.figshare.25583926

In Silico Analysis of the Dual Role of Tumor Microenvironment on Colon Cancer Subtypes

Kehinde, C. T., Livesey, M., Manganyi, Y., & Bendou, H. (2026) · Cancer Informatics · doi:10.1177/11769351261431245

Factors Associated with the Timing of Liver Metastasis After Colorectal Cancer Surgery: A Retrospective Multicenter Study

Liu, X., Zhou, C., Qiu, W., Li, Z., Wei, F., Xiao, T., Mei, S., Huang, F., Zhao, F., & Liu, Q. (2026) · Cancers · doi:10.3390/cancers18152445

Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities

Sadanandam, A., O’Farrell, A. C., Miller, I. S., Hari, P. S., Lärkeryd, A., Venken, T., Arijs, I., Zanella, E. R., Cottino, F., Pinnelli, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.014

Biomarkers and future directions for immunotherapy in microsatellite-stable colorectal cancer: a systematic review

Xu, J., Ni, C., Wang, P., & Qin, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-13054-5

RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients

Malapelle, U., Passiglia, F., Cremolini, C., Reale, M. L., Pepe, F., Pisapia, P., Avallone, A., Cortinovis, D. L., Stefano, A. D., Fassan, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.015 · Cited by 43 · see citing works

ras gene mutations in colorectal cancer

Karnes, W. E., & Jacobs, L. R. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90281-2

The importance of ras mutations for targeted therapy in colon cancer

Haustermans, K. M., & Debucquoy, A. (2012) · Radiotherapy and Oncology

Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma

Vagaja, N., Parry, J., McCallum, D., Thomas, M., & Bentel, J. M. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202969 · Cited by 14 · see citing works

RAS Genes and Cancer

Hayes, T. K., Stratford, J. K., Wang‐Gillam, A., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_7